Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.

Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.

The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: ##STR00001##
wherein A.sup.3 is CR.sup.3A, CR.sup.3AR.sup.3B, N or NR.sup.3C; R.sup.3A, R.sup.3B, R.sup.4A and R.sup.4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R.sup.3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T.sup.1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R.sup.1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R.sup.2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R.sup.3 is substituted or unsubstituted aromatic carbocyclyl or the like; R.sup.4 is a hydrogen atom or a carboxy protecting group.

The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: ##STR00001##
wherein A.sup.3 is CR.sup.3A, CR.sup.3AR.sup.3B, N or NR.sup.3C; R.sup.3A, R.sup.3B, R.sup.4A and R.sup.4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R.sup.3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T.sup.1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R.sup.1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R.sup.2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R.sup.3 is substituted or unsubstituted aromatic carbocyclyl or the like; R.sup.4 is a hydrogen atom or a carboxy protecting group.

Processes for preparing compounds of Formula (1) and Formula (2) are described, wherein X, Y, Z, R.sub.1-R.sub.7, L and n are defined herein. Intermediates useful in the preparation of the compounds of Formula (1) and Formula (2) are also described.

##STR00001##

Processes for preparing compounds of Formula (1) and Formula (2) are described, wherein X, Y, Z, R.sub.1-R.sub.7, L and n are defined herein. Intermediates useful in the preparation of the compounds of Formula (1) and Formula (2) are also described.

##STR00001##

The present invention provides a novel macrocyclic prodrug compound of general Formula (I), a pharmaceutical composition comprising a compound of Formula (I), and a method for treating diseases mediated by HDAC enzymes by administering a compound of Formula (I), wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, A and Z are defined herein.

##STR00001##

Described herein are compounds of the formulae (I)-(III) as well as pharmaceutical compositions comprising such compounds and methods for using such compounds/pharmaceutical compositions for treating Alzheimer's disease.

The present specification provides a heterocyclic compound and an organic light emitting device using the same.

The present specification provides a heterocyclic compound and an organic light emitting device using the same.